Last reviewed · How we verify
NCT01366183
Chemotherapy Toxicity On Quality of Life in Older Patients With Stage I, Stage II, Stage III, or Stage IV Ovarian Epithelial, Primary Peritoneal Cavity, or Fallopian Tube Cancer
trial testing Assessment of Therapy Complications in Stage I Ovarian Cancer AJCC v6 and v7 in 290 participants. Status unknown.
31 December 2021
Quick facts
| Lead sponsor | Gynecologic Oncology Group |
|---|---|
| Status | Status unknown |
| Study type | OBSERVATIONAL |
| Enrollment | 290 |
| Start date | 15 August 2011 |
| Primary completion | 31 December 2021 |
| Sites | 357 locations across United States |
Drugs / interventions tested
- Assessment of Therapy Complications
- Carboplatin (Carboplatin) — full drug profile →
- Filgrastim — full drug profile →
- Paclitaxel — full drug profile →
- Pharmacological Study — full drug profile →
- Quality-of-Life Assessment
- Questionnaire Administration
Conditions studied
- Stage I Ovarian Cancer AJCC v6 and v7 — all drugs for Stage I Ovarian Cancer AJCC v6 and v7 →
- Stage IA Fallopian Tube Cancer AJCC v6 and v7 — all drugs for Stage IA Fallopian Tube Cancer AJCC v6 and v7 →
- Stage IB Fallopian Tube Cancer AJCC v6 and v7 — all drugs for Stage IB Fallopian Tube Cancer AJCC v6 and v7 →
- Stage IC Fallopian Tube Cancer AJCC v6 and v7 — all drugs for Stage IC Fallopian Tube Cancer AJCC v6 and v7 →
Sponsor
Gynecologic Oncology Group — full company profile →
Who can join
75 and older, any sex, with Stage I Ovarian Cancer AJCC v6 and v7 or Stage IA Fallopian Tube Cancer AJCC v6 and v7. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This trial studies the chemotherapy toxicity on quality of life in older patients with stage I, stage II, stage III, or stage IV ovarian epithelial, primary peritoneal cavity, or fallopian tube cancer. Learning about the side effects of chemotherapy in older patients may help doctors plan better ways to treat cancer.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT01366183
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Assessment of Therapy Complications
Trials testing the same drug.
- NCT05790538 — Predicting the Impact of Treatment Toxicities on Health During Cancer ( PATTERN ) · completed
- NCT01790152 — Effects of Dexrazoxane Hydrochloride on Biomarkers Associated With Cardiomyopathy and Heart Failure After Cancer Treatme · recruiting
- NCT01372787 — Quality of Life and Care Needs of Patients With Persistent or Recurrent Ovarian Cancer, Fallopian Tube Cancer, or Perito · unknown
- NCT00736749 — Long-Term Follow-Up of Patients Who Have Participated in Children's Oncology Group Studies · active not recruiting
Other recruiting trials for Stage I Ovarian Cancer AJCC v6 and v7
Currently open trials in the same condition.
- NCT05334069 — Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection · recruiting
Other Gynecologic Oncology Group trials
Trials by the same sponsor.
- NCT04393285 — Abemaciclib and Letrozole to Treat Endometrial Cancer · Phase 2 · active not recruiting
- NCT03673124 — Ribociclib and Letrozole Treatment in Ovarian Cancer · Phase 2 · active not recruiting
- NCT02065687 — Paclitaxel and Carboplatin With or Without Metformin Hydrochloride in Treating Patients With Stage III, IV, or Recurrent · Phase 2, PHASE3 · unknown
- NCT01720173 — Dalantercept in Treating Patients With Recurrent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer · Phase 2 · completed
- NCT01406769 — Bioimpedance Spectroscopy in Detecting Lower-Extremity Lymphedema in Patients With Stage I, Stage II, Stage III, or Stag · Phase 2 · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT01366183 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Gynecologic Oncology Group
- Last refreshed: 30 September 2021
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01366183.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing